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Abstract  Pseudotumoral  lesions  are  uncommon  but  important  to  identity  lesions.  They  can
occur during  inﬂammatory  diseases  (systemic  diseases,  vasculitis,  demyelinating  diseases),
infectious,  and  vascular  diseases.  Also,  in  a  patient  with  a  treated  tumor,  pseudo-progression
and radionecrosis  must  be  differentiated  from  the  tumoral  development.  Diagnosis  can  be  dif-
ﬁcult on  an  MRI  scan,  but  some  MRI  aspects  in  conventional  sequences,  diffusion,  perfusion  and
spectroscopy  can  suggest  the  pseudotumoral  origin  of  a  lesion.  Imaging  must  be  interpreted
according  to  the  context,  the  clinic  and  the  biology.  The  presence  of  associated  intracranial
lesions can  orientate  towards  a  systemic  or  infectious  disease.  A  T2  hyposignal  lesion  suggests
granulomatosis  or  histiocytosis,  especially  if  a  meningeal  or  hypothalamic—pituitary  involve-
ment is  associated.  Non-tumoral  lesions  are  generally  not  hyperperfused.  In  the  absence  of  a
deﬁnitive diagnosis,  the  evolution  of  these  lesions,  whether  under  treatment  or  spontaneous,
is fundamental.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Any  expansive  intracranial  lesion  is  not  necessarily  a tumor.  The  main  diseases  that  can
present  a  pseudotumoral  appearance  are  systemic  diseases,  infectious  lesions,  demyeli-
nating  diseases,  vascular  diseases,  vasculitis  and  radionecrosis.  Their  diagnosis  is  crucial
since  it  can  lead  to  an  important  modiﬁcation  in  the  way  these  lesions  are  managed:  no
biopsy  in  the  case  of  vascular  or  demyelinating  lesions,  close  surveillance  or  biopsy  in
emergency  for  infectious  lesions.  The  diagnosis  of  these  pseudotumoral  lesions  rests  upon
imaging,  clinical  parameters  and  biology.  In  neuroradiology,  some  particular  aspects  or
radiological  associations  can  allude  to  a  pseudotumoral  lesion.
The  purpose  of  this  article  is  to  present  the  main  pseudotumoral  lesions  and  the  way
to  perform  their  diagnosis.
∗ Corresponding author.
E-mail address: del.leclercq@gmail.com (D. Leclercq).
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nCerebral  tumor  or  pseudotumor?  
How to make the diagnosis?
Some  radiological  patterns  are  typical  of  the  non-tumoral
origin  of  a  lesion.
An  open-ring  enhancement  or  a  restricted  demyelinating
front  are  typical  of  demyelinating  lesions.
A  gyriform  enhancement  corresponds  to  a  cortical
enhancement,  which  can  be  seen  in  semi-acute  stroke,  her-
pes  encephalitis  and  status  epilepticus.
A  faint  brush-like  enhancement  with  well-limited  mar-
gins  without  mass  effet  or  T2  WI  hyperintensity  is  typical  of
capillary  telangiectasia.
An  eccentric  target  sign  is  the  hallmark  of  toxoplasmosis.
When  exploring  a  necrotic  lesion,  a  T2  hypointense  rim
with  surrounding  edema  is  suggestive  of  an  abscess  and  must
lead  to  perform  a  diffusion-weighted  sequence.  A  central
restricted  diffusion  conﬁrms  the  presence  of  an  abscess,
which  is  a  diagnosis  and  therapeutic  emergency.
Finally,  an  edematous  bi-thalamic  lesion  with  or  with-
out  haemorrhage  and  non-nodular  contrast  enhancement
must  suggest  a  deep  venous  thrombosis  before  considering
a  tumour.
Except  for  these  radiological  patterns,  the  pseudotu-
moral  nature  of  a  lesion  can  be  considered  when  a  lesions
presents  with  atypical  features  for  a  brain  tumour.  Hence,
to  diagnose  a  pseudo-tumour,  it  is  necessary  to  be  familiar
with  the  typical  aspects  of  tumoral  lesions.
Brain  tumours  can  be  single  or  multiple,  and  are  respon-
sible  for  mass  effect.  This  mass  effect  is  judged  on  the
deformation  of  the  ventricles  and  the  eradication  of  sulcis,
which  must  be  compared  to  the  size  of  the  lesion.  In  gen-
eral,  they  are  in  T2  hypersignal.  The  inﬁltrating  lesions  and
metastasis  are  classically  in  T2  hypersignal  with  increased
ADC,  and  lymphoma,  in  T2  hyposignal  with  decrease  of  the
ADC.
Haemorrhagic  lesions  can  also  present  with  hypo-T2
images  and  restricted  diffusion.
Tumoral  lesions,  apart  from  glial  lesions  with  low-grade
malignancy,  increase  in  a  homogenous  way,  or  partially,  with
possible  necrotic  portions  [1,2].  Glial  lesions  with  high-grade
malignancy  and  metastasis  can  appear  hyperperfused,  since
they  present  with  neoangiogenesis,  with  an  increase  in  rCBV
Figure 1. Neurosarcoidosis. FLAIR axial (a) and T1 after injection of ga
temporal pseudotumoral, in FLAIR hyposignal, enhancing homogeneousl
Associated hypothalamic inﬁltration, enhanced after injection.
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2]. In  spectroscopy,  the  tumoral  inﬁltration  at  the  periphery
f  an  area  of  enhancement  manifests  itself  as  an  increase
f  the  choline  peak  and  a  decrease  of  the  NAA  peak,  and  is
uite  indicative  of  a  glial  lesion  [2]. In  case  of  mass,  a  long
E  choline/NAA  ratio  superior  to  2  is  highly  indicative  of  a
umour  [3].
However,  if  an  intra-axial  lesion  only  brings  about  a
mall  mass  effect,  a  pseudotumoral  lesion  must  be  alluded
o,  particularly  a  demyelinating  disease.  The  masses  in
2  hyposignal,  without  diffusion  hypersignal,  support  gran-
lomatosis  or  histiocytosis,  especially  if  a  meningeal  or
ypothalamic—pituitary  infection  is  associated.  The  cere-
ral  blood  volume  on  the  perfusion  sequence  is  not
igniﬁcantly  increased  in  the  case  of  a  pseudotumoral  lesion,
part  from  in  a  few  rare  cases  (see  infra:  rare  cases  of  neoan-
iogenesis  of  inﬂammatory  lesions  or  injection  in  strokes).
n  increase  in  the  choline  peak  can  exist,  but  in  a  less  higher
atio  than  in  the  case  of  a brain  tumour.
The  evolution  of  lesions  under  medical  treatment  is
bviously  fundamental,  in  particular,  the  response  to
teroids  being  a  major  argument  supporting  the  inﬂamma-
ory  character  of  a  lesion  (apart  from  the  notable  exception
f  primary  cerebral  lymphoma).
Finally,  when  suspecting  a  pseudotumoral  of  a  systemic
r  infectious  origin,  it  is  necessary  to  carry  out  an  emer-
ency  biological  etiologic  assessment  and  a  CT  scan  of  chest,
bdomen  and  pelvis,  in  order  to  conclude  as  quickly  as  pos-
ible,  whether  a  cerebral  biopsy  is  needed  or  not.
ain etiologies of pseudotumoral lesions
nﬂammatory infections
ystemic  diseases
ntra-axial  pseudotumors:  neurosarcoidosis
arcoidosis  is  a  multisystemic  granulomatosis,  characterised
y  the  presence  of  epithelioid  granulomas,  without  caseous
ecrosis  [4].  Even  if  the  sarcoidosis  lesions  are  generallydolinium (b). Parenchymatous lesions, which appear right internal
y after injection and surrounded by oedema in FLAIR hypersignal.
xtra-axial,  actual  intra-axial  masses,  which  appear  pseu-
otumoral,  can  occur.  They  are  most  often  in  T2  hyposignal,
nd  increase  consistently,  with  a  perilesional  oedema
n  T2  hypersignal  [5—7]  (Fig.  1).  These  masses  can  be
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yperperfused,  and  show  an  increase  in  the  choline  peak.
 central  necrosis  is  very  rare  [5].  The  main  distinct
iagnoses  are  represented  by  metastases,  lymphoma-
ype  primary  tumours  and  pseudotumoral  demyelinating
esions.
Neurological  sarcoidosis  localisations  have  the  charac-
eristic  of  often  being  multiple  and  diffused,  affecting  the
rain,  the  CNS  and  cranial  nerves  at  variable  degrees.
 leptomeningeal  increase  is  frequently  associated  with
hese  pseudotumoral  intra-axial  masses,  and  is  considered
s  a  stage  prior  to  the  existence  of  intra-axial  granulomas.
ndeed,  the  deep  extension  of  leptomeningeal  granulomas
long  the  perivascular  spaces  can  be  the  start  of  a  parenchy-
al  inﬁltration  [5].  The  leptomenigeal  infection  manifests
tself  by  a  micronodular  or  linear  increase  in  leptomeninges,
ith  a  predilection  for  the  suprasellar  areas  and  the  base  of
he  skull.  An  inﬁltration  of  the  hypothalamic-pituitary  axis
n  T2  hyposignal  and  increases  in  cranial  nerves  can  also
e  associated  [8]  (Fig.  1).  Hydrocephalus  is  frequent,  by
eningeal  sheathing.
These  lesions  regress  partially  or  fully  under  treatment
ith  corticosteroids  [9].istiocytosis
ifferent  types  of  histiocytosis  are  associated  with  tis-
ue  accumulation  of  histiocytes.  Langerhans  histiocytosis
N
B
i
igure 2. Langerhans histiocytosis. FLAIR axial (a), T1 after injection o
ingle voxel spectroscopy at short TE (35 ms) (d) and long TE (135 ms) (e). 
nhancing homogeneously, surrounded by oedema. The lesion is hyperp
ho/Cr and Cho/NAA connections are increased (> 1), the NAA/Cr conneD.  Leclercq  et  al.
nd  non-Langerhans  histiocytosis  are  distinguished.  Non-
angerhans  histiocytosis  include  Erdheim—Chester  disease,
osai—Dorfman  disease  and  xanthogranulomas.
Supratentorial  intra-axial  masses  and  cerebellar  hemi-
pheres  can  occur  during  all  these  types  of  histiocytosis
10—13].  Most  often,  they  appear  in  T2  hyposignal  and
ncrease  homogeneously.  Most  often,  they  are  in  hypersignal
n  diffusion,  related  to  a T2  effect,  the  ADC  being  usually
oderately  increased.  They  are  responsible  for  a  variable
ass  effect,  according  to  their  size,  and  are  surrounded
y  an  oedema  in  T2  hypersignal  [12].  These  masses  can  be
yperperfused,  with  a  neoangiogenesis  in  anatomopathol-
gy,  and  show  an  increase  in  the  choline  peak  (Fig.  2).  They
an  follow  a  vascular  topography  [10].
Pontine  lesions  can  occur  during  Langerhans  histiocyto-
is,  with  an  irregular  contrast  enhancement  or  following  a
icrovascular  distribution  [10]  (Fig.  3).
The  main  differential  diagnoses  are  metastases  and
ymphomas.  These  lesions,  difﬁcult  to  treat,  can  regress
pontaneously  or  under  treatment  with  corticosteroids
nd/or  chemotherapy  [11,14,15], or  worsen  despite  well-
uided  medical  treatments.euro-Behc¸et’s  disease
ehc¸et’s disease  is  a  systemic  vasculitis.  During  acute
nﬂammatory  phases,  the  wall  of  the  vessels  and  the
f gadolinium (b). Perfusion cartography (cerebral blood volume) (c),
Sub-cortical left frontal infracentimetric lesion in FLAIR hyposignal,
erfused (rCBV at 3.4 times the standard). In the spectroscopy, the
ction lowered (< 1).
Cerebral  tumor  or  pseudotumor?  909
Figure 3. Langerhans histiocytosis. T2 axial (a) and T1 after injection of gadolinium (b). Pontine lesions extended to the middle cerebellar
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cstems and the anterior section of the cerebellar hemispheres, of a he
are surrounded by oedema. The pons is increased in volume.
perivascular  cerebral  parenchyma  are  damaged.  The
oedema  and  the  inﬂammatory  cellular  inﬁltration  can  be
very  signiﬁcant  with,  in  an  MRI,  areas  in  T2  hypersignal  with
a  variable  size,  sometimes  conﬂuent  in  wide  ranges,  and
preferentially  touching  the  pons,  the  mesencephalon  and
the  basal  nuclei,  with  a  possible  extension  to  the  internal
capsules  [6]  (Fig.  4).  Recent  lesions  can  present  with  mass
effect,  contrast  enhancement  and  consequently  present
a  pseudotumoral  appearance  [16—18].  The  main  distinct
diagnoses  are  glial  lesions,  lymphomas  or  infectious  and
granulomatous  lesions.
In the  majority  of  cases,  the  size,  the  mass  effect  and
the  enhancement  of  the  acute  lesions  regress  during  the  ﬁrst
month  of  treatment,  with  possibly  the  complete  disappear-
ance  of  the  lesions.
Extra-axial  pseudotumors:  inﬂammatory  meningeal
masses
Pachymeningeal  masses  can  occur  during  numerous  system
diseases.
The  most  frequently  etiologies  are  sarcoidosis  and
Wegener’s  granulomatosis.  Wegener’s  granulomatosis  is  a
I
T
i
Figure 4. Neuro-Behc¸et’s disease. T2 axial T2 (a) and T1 after inject
cerebellar stem in T2 hypersignal, with micronodular enhancement, pergeneous signal in T2, with micronodular enhancements. The lesions
ystemic  disease,  associating  necrotising  small  vessel  vas-
ulitis  lesions  and  giant-cell  necrotising  and  ulcerating
xtravascular  granulomas.  The  dura  mater  can  be  thickened
n  a  diffuse  or  focal  way.  These  granulomatous  lesions,  sim-
lar  to  meningiomas,  most  often  appear  in  T2  hyposignal,
nd  enhance  rather  peripherally  [6—19].  Focal  dural  masses
uring  Wegener’s  granulomatosis  most  often  correspond  to  a
ransosseous  extension  of  orbital,  sinuses  and  nasal  cavities
esions.
Dural,  pseudo-meningioma  masses,  can  also  be  observed
uring  histiocytoses,  whether  Langerhans  or  non-Langerhans
6,12,20], Churg—Strauss  syndromes  [21]  or  pseudotumoral
gG4  inﬁltrations  [22].  They  present  with  an  intense  T2
yposignal  and  enhance  homogeneously  after  injection.
Intra-ventricular  masses  in  T2  hyposignal  and  homo-
eneous  enhancement  can  occur  during  granulomatoses
23,24]  and  during  histiocytoses.  These  lesions  develop  from
horoid  plexuses  [10]  or  ependymal  cells  [12,23].nﬂammatory  pseudotumors
he  main  differential  diagnosis  of  lesions  occurring  dur-
ng  systemic  or  infectious  diseases,  whether  intra-  or
ion of gadolinium (b). Pontine lesion extended to the left-middle
ilesional oedema with mass effect.
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xtra-axial,  hypointense  in  T2  and  increased  intensely,  more
r  less  homogeneously,  is  the  ‘‘inﬂammatory  pseudotumor’’,
ithout  an  underlying  systemic  disease.  These  masses  are
haracterised  by  the  presence  in  anatomopathology  of  a
on-speciﬁc  inﬂammatory  inﬁltration,  and  the  assessment
earching  for  another  localisation  being  negative.  The  eti-
logy  of  these  infections  is  not  yet  clariﬁed:  they  could
esult  from  an  immune  response  to  an  infectious  agent
EBV,  mycobacteria. .  .). These  lesions  present  highly  vari-
ble  responses  to  medical  treatments  by  corticosteroids
nd/or  immunosuppressants.  A  surgical  resection  or  treat-
ent  by  radiotherapy  can  also  be  proposed  [25—27].
rimary  vasculitis  of  the  CNS
rimary  vasculitis  or  idiopathic  granulomatous  angiitis  of
he  CNS  are  rare  entities  of  vasculitis,  only  reaching  the
NS  and  characterised  in  anatomopathology  by  a  granuloma-
ous  inﬂammatory  infection,  lymphocystic  or  necrotising  the
all  of  the  leptomeningeal  and  intra-parenchymatous  arte-
ioles  [28].  The  most  frequently  reported  lesions  in  an  MRI
re  multiple  and  bilateral  infarctions,  intracranial  haemor-
hages,  and  more  rarely,  thickening  and  enhancements  of
he  artery  walls.  The  MR  artery  angiogram  most  often  is
egative  [28].
Parenchymal  and  leptomeningeal  lesions,  which  appear
seudotumoral,  single  or  multiple,  bilateral  or  only  reach-
ng  a  cerebral  hemisphere  can  be  seen  in  T2  hypersignal,
nhance  homogenously  or  heterogeneously  with  a  possible
ecrotic  appearance  [29,30].  These  pseudotumoral  appear-
nces  accompany  a  perilesional  oedema  and  a  signiﬁcant
ass  effect  [31,32]  (Fig.  5).  The  spectroscopy  is  not  spe-
iﬁc:  the  choline  peak  is  barely  or  not  increased,  and  a  lipid
eak  can  be  observed  [29,31].  The  distinct  diagnoses  are
ominated  by  glial  lesions,  lymphomas  and  demyelinating
iseases.  Development  is  very  variable  under  treatment  with
orticosteroids  and/or  cyclophosphamide-type  chemother-
py  [29].
h
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igure 5. Primary cerebral vasculitis. FLAIR axial (a), T2 coronal (b)
ypersignal and FLAIR, reaching the left cerebral hemisphere with mod
isible in hyposignal in T2 and FLAIR. Signiﬁcant perilesional oedema anD.  Leclercq  et  al.
emyelinating  disease
emyelinating  lesions  can  present  a  pseudotumoral  appear-
nce  related  to  a  signiﬁcant  inﬂammatory  reaction,  with
yperT2  areas  appearing  extensive,  more  than  2  cm  in
iameter.  These  pseudotumoral  forms  (Balo’s  concentric
clerosis,  ADEM,  Schilder’s  disease,  Marburg  virus  disease)
an  mimic  a glial  tumour,  a  lymphoma  or  a  metastasis.
Lesions  appear  in  T2  isosignal  or  hypersignal.  Some  MRI
igns  can  suggest  the  diagnosis  of  demyelinating  disease:
o  or  little  mass  effect  compared  with  the  size  of  the
esion,  an  incomplete  ring  enhancement,  with  in  particu-
ar,  ‘‘C-shape’’  enhancement  of  a sub-cortical  lesions  [33],
 peripheral  border  with  restricted  diffusion  consistent  with
 demyelinating  front  and  the  presence  of  a  normal  vessel
ithin  the  lesion  traducing  the  venular  tropism  of  the  lesions
more  visible  after  injection  or  in  magnetic  susceptibility
maging)  (Fig.  6).  In  the  case  of  Balo’s  concentric  sclerosis,
 characteristic  appearance  with  multiple  concentric  areas
f  demyelination  can  be  seen  in  T2  and  T1  after  injection
34]. On  spectroscopy,  the  choline  peak  is  increased  and  the
resence  of  a  lactate  peak  is  usually  observed.  The  perile-
ional  oedema,  often  barely  signiﬁcant  when  compared  with
he  size  of  the  lesion,  is  partially  or  fully  regressive  under
teroids  [33].  However,  it  is  usually  necessary  to  deliver
igher  corticosteroid  doses  than  in  classic  acute  MS.  The
uration  of  enhancement  of  a  demyelinating  lesion  must  not
xceed  3  months.  Beyond  that,  it  is  necessary  to  allude  to  a
umoral  lesion.
wo  very  rare  entities:  CLIPPERS  and  amyloidoma
LIPPERS  (Chronic  Lymphocytic  Inﬂammation  with  Pontine
erivascular  Enhancement  Responsive  to  Steroids)  is  a  rare
nﬂammatory  disease  of  the  CNS  recently  described  [35].
n  an  MRI,  lesions  are  centred  on  the  pons.  They  appear
eterogeneous  in  T2  hypersignal,  present  a punctiform  and
urvilinear  enhancement,  and  can  extend  to  the  bulb,  to  the
asal  nuclei  and  to  the  cerebellar  white  matter.  They  do  not
ead  to  any  signiﬁcant  mass  effect.  In  pathology,  lymphocytic
 and T1 axial after injection of gadolinium (c). Vast range in T2
erate heterogeneous enhancement and multiple micro bleeding,
d mass effect with subfalcine and left temporal engagement.
Cerebral  tumor  or  pseudotumor?  911
Figure 6. Multiple sclerosis. FLAIR axial (a), diffusion (b), SWI (c), T1 coronal after injection of gadolinium (d). A left juxtaventricular
lesion in FLAIR hypersignal, with peripheral border in hypersignal in diffusion, without perilesional oedema, nor mass effect. In magnetic
susceptibility imaging (SWI), the lesion appears as if it is being penetrated by multiple veins that appear dilated. After injection, the lesion
is enhanced moderately and relatively homogeneously.
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tinﬁltration  is  mainly  constituted  of  T  CD3+  lymphocytes  and
CD20+  lymphocytes.
These  lesions  are  very  sensitive  to  treatments  by  corti-
costeroids  and/or  immunosuppressants  [35].
Cerebral  amyloidomas  are  formed  from  cerebral  deposits
of  amyloid  proteins  with,  in  imaging,  single  or  multiple
intra-axial  masses,  developed  within  the  white  matter  and
which  can  extend  to  the  ventricular  walls.  Most  often,  these
masses  appear  in  T2  hyposignal,  present  little  or  no  mass
effect  and/or  perilesional  oedema,  and  their  enhancement
is  variable:  discrete  or  intense  [36]  (Fig.  7).
Infectious disease
Some  infectious  diseases  can  be  difﬁcult  to  distinguish  from
tumoral  lesions,  and  more  particularly,  from  metastases,
because  of  the  very  frequent  hematogenous  dissemination
of  these  two  entities,  with  a  preferential  localisation  of  the
lesions  at  the  white  matter/grey  matter  junction.  Some  MRI
p
n
t
aspects  allow  the  diagnosis  to  be  steered  towards  an  infec-
ious  disease.
Exploring  unique  or  multiple  sub-cortical  and/or  deep
esions,  of  variable  T2  signal  and  increased  peripherically,
he  presence  of  an  ‘‘eccentric  target  sign’’  (target  lesion
ith  an  eccentric  centre)  is  highly  suggestive  of  toxoplas-
osis.  This  appearance  in  imaging  is  linked  to  the  presence
f  inﬂammatory  vessels  inﬁltrating  to  the  central  section  of
he  lesion  [37]  (Fig.  8).
Cerebral  tuberculomas,  as  well  as  some  parasites
echinococcosis,  brucellosis. . .) have  a  variable  T2  signal,
nd  can  present  a  homogeneous  or  heterogeneous  ring  or
luster  enhancement  [38].
Perfusion  analysis  of  the  wall  from  these  lesions  can
llow  them  to  be  distinguished  from  glioblastomas  or  metas-
ases:  the  rCBV  ratio  measured  between  the  increased  lesion
eripheral  after  injection  and  the  healthy  brain  tissue  is  sig-
iﬁcantly  lower  in  the  case  of  infectious  lesions  (rCBV  <  1)
han  in  cases  of  high-grade  tumoral  lesions  (rCBV  >  5  on  aver-
ge)  [39].
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Figure 7. Amyloidoma. T2 coronal T2 (a) and T1 after injection (b). Residual right temporal lesion, in contact with the postoperative
cavity, in T2 hyposignal and enhanced moderately and homogeneously, without signiﬁcant perilesional oedema.
Figure 8. Toxoplasmosis. FLAIR axial (a) and T1 after injection (b). Multiple sub-cortical and deep lesions, enhanced after injection,
surrounded by oedema. The most voluminous lesion, right occipital, presents a content in FLAIR hyposignal and a typical target enhancement
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ascular diseases
n  ischemic  stroke  at  the  sub-acute  phase  (between  day
 and  2  weeks)  appears  in  T2  hypersignal,  present  a  mass
ffect  with  eradication  of  sulci  related  to  a  vasogenic
edema,  a  gyriform  or  heterogeneous  enhancement  relating
o  the  rupture  of  the  blood-brain  barrier,  which  can  per-
ist  for  up  to  10  weeks  after  the  stroke,  and  can  present
ith  hyperperfusion  known  as  ‘‘luxury  perfusion’’,  through
yperaemia  [40]  (Fig.  9).  Some  ischemic  lesions  can  enhance
omogeneously  at  the  sub-acute  phase,  particularly  cere-
ellar  lacunar  or  basal  nuclei  infarcts.  The  appearance  on
pectroscopy  is  equally  misleading,  with  a  fall  in  metabo-
ites,  sparing  of  the  choline,  which  therefore  appears  falsely
ncreased,  and  the  presence  of  free  lipids  and  lactates
Fig.  9).  Consequently,  stroke  at  the  sub-acute  phase  can
imulate  a  tumoral  lesion.Venous  infarctions,  related  to  deep  vein  thrombosis,  can
lso  be  misdiagnosed  as  glioma  or  lymphoma-type  tumoral
esions,  more  particularly  when  they  are  unilateral  [41].
ndeed,  a  venous  infarction  can  present  itself  in  an  MRI
T
H
bn  the  form  of  a unilateral  thalamic  oedema,  more  or  less
xtended  to  the  white  matter  and  to  the  basal  nuclei,  in  T2
ypersignal,  associated  with  possible  (micro)  bleeding  and
 discrete  and  heterogeneous  enhancement.  Mass  effect  is
ommon.
Finally,  capillary  telangiectasias  are  vascular  mal-
ormations,  constituted  of  capillaries  dilated  within  a
ealthy  cerebral  parenchyma.  They  can  be  subtentorial,
ocalised  to  the  pons,  or  supratentorial.  These  malfor-
ations  exert  no  mass  effect,  appear  in  isosignal  or
n  T2  discrete  hypersignal,  in  isosignal  in  T1  discrete
yposignal,  and  enhance  moderately,  and  homogeneously
fter  injection.  The  T2*  and  SWI  sequences  allow  the
iagnosis  to  be  alluded  to,  with  a  clear  hyposignal  com-
onent  of  the  malformation  over  these  2  sequences  [42]
Fig.  10).umoral pseudo-progression and radionecrosis
igh-grade  glial  tumours  and  metastases  can  be  treated
y  surgery  then  simultaneous  radio-  and  chemotherapies.
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Figure 9. Transient ischemic attack at the sub-acute phase. Axial diffusion (a), FLAIR (b), T1 after injection (c). Cartography of perfusion
(cerebral blood volume) (d). Spectroscopy at short TE (35 ms) (e) and long (135 ms) (f). Lesion in the area of the left posterior cerebral
artery with a cortical strip in diffusion hypersignal, FLAIR, and with gyriform enhancement and associated vasogenic oedema. The lesion
exerts a mass effect with left temporal engagement. It is hyperperfused at 4 times the standard, by hyperaemia. In the spectroscopy, fall
in metabolites, apart from choline, which appears falsely increased and presence of free lipids.
t
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aThe  evaluation  of  the  tumoral  response  is  traditionally
evaluated  according  to  the  MacDonald  criteria,  based  on
analysing  the  volume  of  lesional  enhancement.  These  crite-
ria  present  signiﬁcant  limits,  as  the  lesional  enhancement
can  also  be  the  reﬂection  of  the  disruption  of  the  blood-brain
barrier  by  different  mechanisms:  post-surgical  reorgani-
sation,  ischemia,  local  inﬂammation  to  the  stopping  of
radiotherapy  with  an  appearance  of  pseudo-progression
or  phenomena  of  radionecrosis  (acute,  sub-acute  or
delayed,  in  the  18—24  months  following  the  treatment  being
stopped).  During  tumoral  progression,  pseudo-progression
and  radionecrosis,  a  perilesional  oedema  and  an  increase  in
o
r
o
bhe  lesional  enhancement,  sometimes  major,  can  occur.  Con-
entional  sequences  do  not  allow  the  tumoral  progression
f  the  pseudo-progression  or  the  radionecrosis  to  be  distin-
uished  with  certainty,  unlike  the  sequences  of  spectroscopy
nd  perfusion,  which  can  demonstrate  a  NAA  decay,  a  mod-
rate  increase  in  choline  with  a cho/NAA  connection  <  1.9
ong  TE,  the  presence  of  a  signiﬁcant  peak  in  lipids/lactates,
nd  an  un-increased  rCBV  in  the  case  of  pseudo-progression
r  radionecrosis  [3,43]. In  case  of  doubt,  it  is  advised  to
e-perform  the  examination  closer  (one  month),  the  devel-
pment  of  parameters  from  the  spectroscopy  and  perfusion
eing  more  speciﬁc  than  their  absolute  value.
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Figure 10. Capillary telangiectasia. FLAIR axial (a), T1 (b), T1 after injection (c), T2* (d). Mesencephalic lesion in FLAIR and T1 isosignal,
T2* hyposignal, and enhanced after injection with a striped appearance linked to multiple dilated capillaries. Absence of perilesional oedema
and mass effect.
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 great  variety  of  inﬂammatory,  infectious  and  vascular  dis-
ases  can  present  themselves  in  the  form  of  intracranial
asses,  which  appear  pseudotumoral.  The  differential  diag-
osis  between  tumor  and  pseudotumor  can  therefore  can  be
omplex.
TAKE-HOME  MESSAGES
• MRI  appearances  being  able  to  allude  to  a
pseudotumoral  lesion:
◦ Little  or  no  mass  effect;
◦ Lesions  in  T2  hyposignal  with  normal  or  increased
ADC;
◦ 3  particular  enhancements:  in  open-ring
(demyelinating  disease),  gyriform  (TIA)  and
‘‘eccentric  target  sign’’  (toxoplasmosis);
◦ No  signiﬁcant  lesional  hyperperfusion  with  a
rCBV  <  1.75;◦ Choline  peak,  has  not  or  has  barely  increased  with
choline/Cr  at  long  TE  <  2.
Q
1•  Pseudotumoral  lesions  in  T2  hyposignal  and  enhanced:
◦  Granulomatosis,  histiocytosis,  Behc¸et’s Disease,
Churg—Strauss  Syndrome,  IgG4  inﬁltration;
◦  Inﬂammatory  pseudotumor;
◦  Amyloidoma;
◦  Tuberculoma.
•  Pseudotumoral  lesions  of  the  brain  stem:
◦  Langerhans  histiocytosis;
◦ Neuro-Behc¸et’s disease;
◦  CLIPPERS;
◦  Demyelinating  lesion;
◦  Capillary  telangiectasia.
linical case
emale  of  49  years  old  with  medical  history  of  diabetes
nsipidus  and  infertility.  Loss  of  consciousness  (Fig.  11).uestions
.  How  would  you  describe  the  cerebral  lesions?
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 coron
sectio
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c
RFigure 11. FLAIR axial (a), T1 after injection (b), diffusion (c), T1
centred on the juxtaventricular lesion of the right ventricular inter
2.  What  are  the  three  main  diagnoses  to  allude  to  when
faced  with  this  type  of  lesional  association?
3.  In  this  case,  which  MRI  appearances  must  a  pseudotu-
moral  lesion  rather  be  alluded  to?
Answers
1.  The  MRI  highlights  several  intracranial  lesions:
•  a  juxtaventricular  lesion  in  the  area  of  the  right
ventricular  intersection,  in  FLAIR  hyposignal  and  dif-
fusion,  and  enhanced  homogeneously  after  injection.
This  lesion  is  surrounded  by  a  signiﬁcant  oedema  in
FLAIR  hypersignal.  On  spectroscopy,  the  choline/Cr  and
cho/NAA  ratios  are  increased.  No  lipid  peak  can  be
seen;
•  a  juxtaventricular  lesion,  enhanced  after  injection  on
contact  with  the  anterior  horn  of  the  right  lateral  ven-
tricle;
•  a  sub-cortical  left  insular  nodular  lesion,  enhanced
after  injection  and  surrounded  by  an  oedema  in  FLAIR
hypersignal;
•  a  diffused  and  nodular  thickening  of  the  pituitary  stem,
enhanced  after  injection.
2.  Facing  juxtaventricular  sub-cortical  and  pituitary  stem
lesions,  neurosarcoidosis,  histiocytosis  and  a  primary
cerebral  lymphoma  can  be  alluded  to.
3.  The  lesion  in  the  area  of  the  right  ventricular  intersec-
tion  is  in  FLAIR  hyposignal  and  diffusion.  A  lymphomatousal after injection (d), single voxel spectroscopy at long TE (135 ms)
n (e).
localisation  should  appear  in  FLAIR  hyposignal  and  dif-
fusion  hypersignal.  In  the  spectroscopy,  no  lipid  peak,
characteristic  of  a  lymphomatous  localisation  is  seen.
iagnosis
eurosarcoidosis.
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